Radius: A phase 2, randomized trial of standard of care (SOC) with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients (pts) with FLT3-Itd-mutated acute myeloid leukemia (AML)

Authors
Category Primary study
JournalBlood
Year 2016
This article has no abstract
Epistemonikos ID: 232f7aa613072020b77e39cce31dd6caf636970e
First added on: Feb 08, 2025